Permissive State of EMT: The Role of Immune Cell Compartment
- PMID: 32391271
- PMCID: PMC7189417
- DOI: 10.3389/fonc.2020.00587
Permissive State of EMT: The Role of Immune Cell Compartment
Abstract
The Epithelial to Mesenchymal Transition (EMT) type 3 is a reversible dynamic process recognized as a major determinant of the metastatic event, although many questions regarding its role throughout this process remain unanswered. The ability of cancer cells to migrate and colonize distant organs is a key aspect of tumor progression and evolution, requiring constant tumor cells and tumor microenvironment (TME) changes, as well as constant changes affecting the cross-talk between the two aforementioned compartments. Alterations affecting tumor cells, such as transcription factors, trans-membrane receptors, chromatin remodeling complexes and metabolic pathways, leading to the disappearance of the epithelial phenotype and concomitant gaining of the undifferentiated mesenchymal phenotype are undoubtedly major players of the EMT process. However, several lines of evidence point out toward a more critical role of TME composition in creating an "EMT-permissive state." The "EMT-permissive state" consists in changes affecting physical and biochemical properties (i.e., stiffness and/or hypoxia) as well as changes of the TME cellular component (i.e., immune-cell, blood vessel, lymphatic vessels, fibroblasts, and fat cells) that favor and induce the epithelial mesenchymal transition. In this mini review, we will discuss the role of the tumor microenvironment cellular component that are involved in supporting the EMT, with particular emphasis on the immune-inflammatory cells component.
Keywords: EMT; TGF-β; Treg; cytotoxic T cells; inflammatory cytokines.
Copyright © 2020 Fedele and Melisi.
Similar articles
-
TGF-β-induced epithelial-mesenchymal transition: a link between cancer and inflammation.Semin Cancer Biol. 2012 Oct;22(5-6):455-61. doi: 10.1016/j.semcancer.2012.05.004. Epub 2012 May 22. Semin Cancer Biol. 2012. PMID: 22627188 Review.
-
Cross-Talk Between Tumor Cells Undergoing Epithelial to Mesenchymal Transition and Natural Killer Cells in Tumor Microenvironment in Colorectal Cancer.Front Cell Dev Biol. 2021 Nov 10;9:750022. doi: 10.3389/fcell.2021.750022. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34858978 Free PMC article. Review.
-
Synergistic effects of particulate matter and substrate stiffness on epithelial-to-mesenchymal transition.Res Rep Health Eff Inst. 2014 Nov;(182):3-41. Res Rep Health Eff Inst. 2014. PMID: 25669020
-
The Inflammatory Profile of the Tumor Microenvironment, Orchestrated by Cyclooxygenase-2, Promotes Epithelial-Mesenchymal Transition.Front Oncol. 2021 Jun 10;11:686792. doi: 10.3389/fonc.2021.686792. eCollection 2021. Front Oncol. 2021. PMID: 34178680 Free PMC article. Review.
-
Tumor microenvironment and noncoding RNAs as co-drivers of epithelial-mesenchymal transition and cancer metastasis.Dev Dyn. 2018 Mar;247(3):405-431. doi: 10.1002/dvdy.24548. Epub 2017 Sep 18. Dev Dyn. 2018. PMID: 28691356 Review.
Cited by
-
Revisiting Treatment Strategies: Addressing Epithelial-to-Mesenchymal Transition-Induced Resistance in Hepatocellular Carcinoma.BME Front. 2025 Jun 24;6:0144. doi: 10.34133/bmef.0144. eCollection 2025. BME Front. 2025. PMID: 40556662 Free PMC article. Review.
-
Single-cell profiling reveals molecular basis of malignant phenotypes and tumor microenvironments in small bowel adenocarcinomas.Cell Discov. 2022 Sep 14;8(1):92. doi: 10.1038/s41421-022-00434-x. Cell Discov. 2022. PMID: 36104333 Free PMC article.
-
Cancer drug resistance induced by EMT: novel therapeutic strategies.Arch Toxicol. 2021 Jul;95(7):2279-2297. doi: 10.1007/s00204-021-03063-7. Epub 2021 May 18. Arch Toxicol. 2021. PMID: 34003341 Free PMC article. Review.
-
Intratumoural administration and tumour tissue targeting of cancer immunotherapies.Nat Rev Clin Oncol. 2021 Sep;18(9):558-576. doi: 10.1038/s41571-021-00507-y. Epub 2021 May 18. Nat Rev Clin Oncol. 2021. PMID: 34006998 Free PMC article. Review.
-
Analysis of immune subtypes across the epithelial-mesenchymal plasticity spectrum.Comput Struct Biotechnol J. 2021 Jun 17;19:3842-3851. doi: 10.1016/j.csbj.2021.06.023. eCollection 2021. Comput Struct Biotechnol J. 2021. PMID: 34306571 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources